Perceptions of Multiple Sclerosis Patients Receiving Mitoxantrone Chemotherapy Correlated with Quality of Life Indicators

2.50
Hdl Handle:
http://hdl.handle.net/10755/148746
Type:
Presentation
Title:
Perceptions of Multiple Sclerosis Patients Receiving Mitoxantrone Chemotherapy Correlated with Quality of Life Indicators
Abstract:
Perceptions of Multiple Sclerosis Patients Receiving Mitoxantrone Chemotherapy Correlated with Quality of Life Indicators
Conference Sponsor:Sigma Theta Tau International
Conference Year:2007
Author:Moore, Linda A., EdD, MSN
P.I. Institution Name:University of North Carolina at Charlotte
Title:Associate Professor
[Clinical session research presentation] Research Objective: Patient centered shared decision making for treatment of Multiple Sclerosis, MS, is a dynamic process for this chronic progressive, debilitating, incurable disease. Engaging patients in decisions to begin, continue, or stop potentially lethal treatments with hope of only reduce disease progression and/or improve quality of life without affecting longevity, epitomizes decisional complexity and uncertainty. The purpose of this study was to assess patient perceptions and expectations of chemotherapy related to actual clinical changes in their decision process. Study Design:  A repeated measure pre and post design was used to identify patterns of change in quality of life and symptoms. Participants were assessed over time at baseline prior to and 3 weeks after infusions, with every 3 month dosage using the Functional Assessment of Multiple Sclerosis and a MS symptom visual analogue scale. Population: Twenty primarily female Caucasian subjects enrolled. The approximate time since diagnosis was from 1 year for the very aggressive form of MS, to over 10 years for secondary progressive. Principal findings: Data for the expectations, perceptions of treatment have indicated perceptions of benefits, side effects, and clinical status changed over time. Conclusion: Previous clinical research, from neurological assessment and MRIs, found the drug to be beneficial, but there were no data prior to this study on patient's perceived expectations, benefits, or adverse effects that would contribute to the complex decision of agreeing with recommendations for a high risk treatment with uncertain outcomes either from benefits or side effects. Implications: Health care providers need to be consciously aware of patient perceptions and expectations continuously during this on going difficult decision of therapy with uncertain benefits, and uncertain short and long term effects. Patient preferences for adhering to recommended therapy is a shared decision making, dynamic process.
Repository Posting Date:
26-Oct-2011
Date of Publication:
17-Oct-2011
Sponsors:
Sigma Theta Tau International

Full metadata record

DC FieldValue Language
dc.typePresentationen_GB
dc.titlePerceptions of Multiple Sclerosis Patients Receiving Mitoxantrone Chemotherapy Correlated with Quality of Life Indicatorsen_GB
dc.identifier.urihttp://hdl.handle.net/10755/148746-
dc.description.abstract<table><tr><td colspan="2" class="item-title">Perceptions of Multiple Sclerosis Patients Receiving Mitoxantrone Chemotherapy Correlated with Quality of Life Indicators</td></tr><tr class="item-sponsor"><td class="label">Conference Sponsor:</td><td class="value">Sigma Theta Tau International</td></tr><tr class="item-year"><td class="label">Conference Year:</td><td class="value">2007</td></tr><tr class="item-author"><td class="label">Author:</td><td class="value">Moore, Linda A., EdD, MSN</td></tr><tr class="item-institute"><td class="label">P.I. Institution Name:</td><td class="value">University of North Carolina at Charlotte</td></tr><tr class="item-author-title"><td class="label">Title:</td><td class="value">Associate Professor</td></tr><tr class="item-email"><td class="label">Email:</td><td class="value">lmoore@uncc.edu</td></tr><tr><td colspan="2" class="item-abstract">[Clinical session research presentation] Research Objective: Patient centered shared decision making for treatment of Multiple Sclerosis, MS, is a dynamic process for this chronic progressive, debilitating, incurable disease. Engaging patients in decisions to begin, continue, or stop potentially lethal treatments with hope of only reduce disease progression and/or improve quality of life without affecting longevity, epitomizes decisional complexity and uncertainty.&nbsp;The purpose of this study was to assess patient perceptions and expectations of chemotherapy related to actual clinical changes in their decision process. Study Design:&nbsp; A repeated measure pre and post design was used to identify patterns of change in quality of life and symptoms.&nbsp;Participants were assessed over time at baseline prior to and 3 weeks after infusions, with every 3 month dosage using the Functional Assessment of Multiple Sclerosis and a MS symptom visual analogue scale. Population:&nbsp;Twenty primarily female Caucasian subjects enrolled. The approximate time since diagnosis was from 1 year for the very aggressive form of MS, to over 10 years for secondary progressive.&nbsp;Principal findings:&nbsp;Data for the expectations, perceptions of treatment have indicated perceptions of benefits, side effects, and clinical status changed over time. Conclusion:&nbsp;Previous clinical research, from neurological assessment and MRIs, found the drug to be beneficial, but there were no data prior to this study on patient's perceived expectations, benefits, or adverse effects that would contribute to the complex decision of agreeing with recommendations for a high risk treatment with uncertain outcomes either from benefits or side effects. Implications:&nbsp;Health care providers need to be consciously aware of patient perceptions and expectations continuously during this on going difficult decision of therapy with uncertain benefits, and uncertain short and long term effects. Patient preferences for adhering to recommended therapy is a shared decision making, dynamic process.</td></tr></table>en_GB
dc.date.available2011-10-26T09:49:58Z-
dc.date.issued2011-10-17en_GB
dc.date.accessioned2011-10-26T09:49:58Z-
dc.description.sponsorshipSigma Theta Tau Internationalen_GB
All Items in this repository are protected by copyright, with all rights reserved, unless otherwise indicated.